2 results
Approved WMOCompleted
The primary objective of this study is to study the pharmacokinetic characteristics and safety of intranasal administration of midazolam in elderly volunteers.
Approved WMORecruiting
To compare the 120 mg once daily (QD) dose and 200 mg QD dose of MK*6482with respect to objective response rate (ORR) based on Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR).